Nathan Berman communicating with investors over Pfizer project
While shoring up the former Pfizer headquarters in Midtown East, its developer is also looking to shore up investor support. MetroLoft’s Nathan Berman has been talking to investors of the office-to-residential project since Tuesday’s incident, the New York Times reported. Berman’s ability to meet the construction timeline relies not just on the ability to resume work at 235 East 42nd Street, but to hold on to his financing. Berman told investors that there would be relatively minor delays, but that the project would be completed next year, as intended. Berman has said he only expects the delay to last a […]
This article originally appeared on The Real Deal. Click here to read the full story.
Categories
Recent Posts

Why this Brooklyn project is nowhere to be seen

Elliman’s AI overhaul raises questions about future of
agents

Pfizer building scare tests office-to-resi
thesis

NY Dirt: Owners have a lot of pied-à-terre questions

NYC’s top deals: UWS megamansion trades for $40M — nearly
50% off asking

UWS double-wide sells for $45M, sets neighborhood townhouse
record

BroadRange Logistics sued for tenant improvement fraud
scheme

Trump administration rejects Congress’ plan, threatening
vouchers

Chelsea NYCHA redevelopment greenlit after court lifts
pause


